Psyence Group Provides Corporate Update Following Succesful SPAC Spin Out Of Therapeutic Division

2024-03-11T14:36:36+02:00March 11, 2024|Press Releases, Investor Information, Psychedelic News|

Psyence Biomed II Corp. ("Psyence Biomed"), the therapeutics division of Psyence Group and target business of the Business Combination, is now a wholly-owned subsidiary of NASDAQ traded PBM.